Ly01008

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Ly01008 is under investigation for its potential use in colorectal cancer treatment. Its clinical efficacy and safety profile are currently being evaluated in ongoing clinical trials, with preliminary results indicating possible benefits in certain patient populations; however, it has not yet been approved by regulatory agencies such as the FDA.

Mechanism of Action

Ly01008 is an investigational agent with a mechanism of action that targets specific pathways involved in colorectal cancer progression, though detailed mechanisms are not yet fully elucidated and require further research.

Side Effects

Nausea; Fatigue; Diarrhea; Hematological toxicity

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05110118 Phase 1
Archived
Pharmacokinetic Characteristics, Safety, Tolerability and Immunogenicity of LY01008 and Avastin in Healthy Chinese Male Subjects
China

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.